Treatment of Obesity
The invention consists in a method of inducing lipid oxidation or increasing insulin sensitivity through the administration of a ligand which binds to the IL-6 receptor and signals via a gp130/LIF (leukemia inhibitory factor) receptor heterodimer. The chimeric ligand has the potential to be a highly effective therapy for obesity. Through this new methodology for increasing lipid oxidation there is no induction of an inflammatory state, no high concentrations of cytokine need to be used and no autoantibodies will be generated. The invention is particularly useful in treating subjects suffering from symptoms caused by obesity, excessive appetite and overweight, as well as obesity-associated metabolic disorders such as hypertension, osteoarthritis, type II diabetes, increased blood pressure, stroke and heart disease.
Further Information: PDF
Patent- und Verwertungsagentur für die Wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH (PVA SH)
Phone: +49 (0)431/8009937
Contact
Dr. Alexandra Baumgartner
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Sea slugs inspire highly stretchable biomedical sensor
USC Viterbi School of Engineering researcher Hangbo Zhao presents findings on highly stretchable and customizable microneedles for application in fields including neuroscience, tissue engineering, and wearable bioelectronics. The revolution in…
Twisting and binding matter waves with photons in a cavity
Precisely measuring the energy states of individual atoms has been a historical challenge for physicists due to atomic recoil. When an atom interacts with a photon, the atom “recoils” in…
Nanotubes, nanoparticles, and antibodies detect tiny amounts of fentanyl
New sensor is six orders of magnitude more sensitive than the next best thing. A research team at Pitt led by Alexander Star, a chemistry professor in the Kenneth P. Dietrich…
